Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

141
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis.

JNCI cancer spectrum·2026
Same author

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Cancers·2026
Same author

Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma.

Annals of surgical oncology·2026
Same author

CLO26-074: A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CLO26-074: A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

International journal of cancer·2026

Related Experiment Video

Updated: Jun 27, 2025

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
10:31

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma

Published on: August 9, 2016

12.8K

Contemporary outcomes for resected type 1-3 gastroesophageal junction adenocarcinoma: a single-center experience.

Zachary E Stiles1, Brendan L Hagerty1, Maureen Brady1

  • 1Division of Surgical Oncology, Department of Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|May 4, 2024
PubMed
Summary

Surgical outcomes for gastroesophageal junction adenocarcinoma improved over a decade. Siewert type I tumors independently predicted worse survival in resected patients.

Keywords:
EsophagectomyGastroesophageal junctionSiewert

More Related Videos

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

679
Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis
10:41

Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis

Published on: December 15, 2023

1.8K

Related Experiment Videos

Last Updated: Jun 27, 2025

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
10:31

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma

Published on: August 9, 2016

12.8K
Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

679
Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis
10:41

Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis

Published on: December 15, 2023

1.8K

Area of Science:

  • Oncology
  • Surgical Gastroenterology
  • Clinical Outcomes Research

Background:

  • Surgical resection is the primary treatment for gastroesophageal junction (GEJ) tumors.
  • Limited contemporary data exists on Western experiences with GEJ adenocarcinoma resection.

Purpose of the Study:

  • To analyze outcomes of resected GEJ adenocarcinoma based on Siewert classification.
  • To assess trends in operative outcomes and survival over time.

Main Methods:

  • Retrospective analysis of 302 patients with GEJ adenocarcinoma undergoing resection (2012-2022).
  • Patients were classified by Siewert subtype (I, II, III).
  • Pathologic variables, treatment, and outcomes were assessed.

Main Results:

  • Operative outcomes improved over the study period, with lower morbidity and shorter hospital stays in the latter half.
  • Siewert type I tumors showed a higher incidence of signet ring cells compared to types II/III.
  • Three-year overall survival varied significantly by Siewert subtype (Type I: 60.0%, Type II: 77.2%, Type III: 86.3%).

Conclusions:

  • Surgical outcomes for resected GEJ adenocarcinoma have improved.
  • Siewert type I classification is an independent predictor of poorer survival following resection.